271 related articles for article (PubMed ID: 22480869)
21. Self-crosslinked human serum albumin nanocarriers for systemic delivery of polymerized siRNA to tumors.
Son S; Song S; Lee SJ; Min S; Kim SA; Yhee JY; Huh MS; Chan Kwon I; Jeong SY; Byun Y; Kim SH; Kim K
Biomaterials; 2013 Dec; 34(37):9475-85. PubMed ID: 24050874
[TBL] [Abstract][Full Text] [Related]
22. Sequential intravenous injection of anionic polymer and cationic lipoplex of siRNA could effectively deliver siRNA to the liver.
Hattori Y; Arai S; Okamoto R; Hamada M; Kawano K; Yonemochi E
Int J Pharm; 2014 Dec; 476(1-2):289-98. PubMed ID: 25290812
[TBL] [Abstract][Full Text] [Related]
23. Cytoplasm-responsive nanocarriers conjugated with a functional cell-penetrating peptide for systemic siRNA delivery.
Tanaka K; Kanazawa T; Horiuchi S; Ando T; Sugawara K; Takashima Y; Seta Y; Okada H
Int J Pharm; 2013 Oct; 455(1-2):40-7. PubMed ID: 23911914
[TBL] [Abstract][Full Text] [Related]
24. Mono-methoxy-poly(3-hydroxybutyrate-co-4-hydroxybutyrate)-graft-hyper-branched polyethylenimine copolymers for siRNA delivery.
Zhou L; Chen Z; Chi W; Yang X; Wang W; Zhang B
Biomaterials; 2012 Mar; 33(7):2334-44. PubMed ID: 22154621
[TBL] [Abstract][Full Text] [Related]
25. Enhanced siRNA delivery using oleic acid derivative of polyethylenimine.
Teng L; Xie J; Teng L; Lee RJ
Anticancer Res; 2012 Apr; 32(4):1267-71. PubMed ID: 22493358
[TBL] [Abstract][Full Text] [Related]
26. Enhanced cytoplasmic delivery of siRNA using a stabilized polyion complex based on PEGylated nanogels with a cross-linked polyamine structure.
Tamura A; Oishi M; Nagasaki Y
Biomacromolecules; 2009 Jul; 10(7):1818-27. PubMed ID: 19505137
[TBL] [Abstract][Full Text] [Related]
27. Suppression of tumor growth by systemic delivery of anti-VEGF siRNA with cell-penetrating peptide-modified MPEG-PCL nanomicelles.
Kanazawa T; Sugawara K; Tanaka K; Horiuchi S; Takashima Y; Okada H
Eur J Pharm Biopharm; 2012 Aug; 81(3):470-7. PubMed ID: 22579732
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.
Landen CN; Chavez-Reyes A; Bucana C; Schmandt R; Deavers MT; Lopez-Berestein G; Sood AK
Cancer Res; 2005 Aug; 65(15):6910-8. PubMed ID: 16061675
[TBL] [Abstract][Full Text] [Related]
29. [Silence of VEGFR2 expression mediated by PEI/siRNA complexes].
Yang H; Che O; Chen S; Sun L; Ji AM
Yao Xue Xue Bao; 2010 May; 45(5):576-81. PubMed ID: 20931758
[TBL] [Abstract][Full Text] [Related]
30. Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy.
Yang XZ; Dou S; Sun TM; Mao CQ; Wang HX; Wang J
J Control Release; 2011 Dec; 156(2):203-11. PubMed ID: 21839126
[TBL] [Abstract][Full Text] [Related]
31. N-acetylgalactosamine functionalized mixed micellar nanoparticles for targeted delivery of siRNA to liver.
Wang HX; Xiong MH; Wang YC; Zhu J; Wang J
J Control Release; 2013 Mar; 166(2):106-14. PubMed ID: 23266452
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic effects of signal transducer and activator of transcription 3 siRNA on human breast cancer in xenograft mice.
Yang Z; Cai JH; Xie SJ; Li GX; Song WQ; Yan QH; Yan L; Zhang F
Chin Med J (Engl); 2011 Jun; 124(12):1854-61. PubMed ID: 21740845
[TBL] [Abstract][Full Text] [Related]
33. Investigation of the performance of PEG-PEI/ROCK-II-siRNA complexes for Alzheimer's disease in vitro.
Liu Y; Liu Z; Wang Y; Liang YR; Wen X; Hu J; Yang X; Liu J; Xiao S; Cheng D
Brain Res; 2013 Jan; 1490():43-51. PubMed ID: 23103413
[TBL] [Abstract][Full Text] [Related]
34. Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing.
Bartlett DW; Davis ME
Biotechnol Bioeng; 2007 Jul; 97(4):909-21. PubMed ID: 17154307
[TBL] [Abstract][Full Text] [Related]
35. Effective delivery of siRNA into cancer cells and tumors using well-defined biodegradable cationic star polymers.
Boyer C; Teo J; Phillips P; Erlich RB; Sagnella S; Sharbeen G; Dwarte T; Duong HT; Goldstein D; Davis TP; Kavallaris M; McCarroll J
Mol Pharm; 2013 Jun; 10(6):2435-44. PubMed ID: 23611705
[TBL] [Abstract][Full Text] [Related]
36. Potential use of lactosylated dendrimer (G3)/α-cyclodextrin conjugates as hepatocyte-specific siRNA carriers for the treatment of familial amyloidotic polyneuropathy.
Hayashi Y; Mori Y; Yamashita S; Motoyama K; Higashi T; Jono H; Ando Y; Arima H
Mol Pharm; 2012 Jun; 9(6):1645-53. PubMed ID: 22510029
[TBL] [Abstract][Full Text] [Related]
37. Targeted polymeric micelles for siRNA treatment of experimental cancer by intravenous injection.
Christie RJ; Matsumoto Y; Miyata K; Nomoto T; Fukushima S; Osada K; Halnaut J; Pittella F; Kim HJ; Nishiyama N; Kataoka K
ACS Nano; 2012 Jun; 6(6):5174-89. PubMed ID: 22575090
[TBL] [Abstract][Full Text] [Related]
38. The suppression of lung tumorigenesis by aerosol-delivered folate-chitosan-graft-polyethylenimine/Akt1 shRNA complexes through the Akt signaling pathway.
Jiang HL; Xu CX; Kim YK; Arote R; Jere D; Lim HT; Cho MH; Cho CS
Biomaterials; 2009 Oct; 30(29):5844-52. PubMed ID: 19640582
[TBL] [Abstract][Full Text] [Related]
39. [Experimental study of MAT1 gene silencing mediated by siRNA in pancreatic cancer].
Liu JP; Yuan SZ; Zhang SN
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(38):2719-23. PubMed ID: 18167254
[TBL] [Abstract][Full Text] [Related]
40. The therapeutic efficiency of FP-PEA/TAM67 gene complexes via folate receptor-mediated endocytosis in a xenograft mice model.
Arote RB; Hwang SK; Lim HT; Kim TH; Jere D; Jiang HL; Kim YK; Cho MH; Cho CS
Biomaterials; 2010 Mar; 31(8):2435-45. PubMed ID: 20022105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
